Impact of oxaliplatin and trastuzumab combination therapy on tumor markers and T lymphocyte subsets for advanced gastric cancer

BACKGROUND Advanced gastric cancer(AGC)remains a challenging malignancy with poor prognosis.The combination of oxaliplatin and trastuzumab has shown promising results in AGC treatment.This study aimed to investigate the effects of oxaliplatin and trastuzumab combination therapy on serum tumor markers and T lymphocyte subsets in patients with AGC and to explore their potential as predictive biomarkers for treatment response.AIM To investigate the impact of oxaliplatin and trastuzumab combination therapy on serum markers and T cell subsets in patients with AGC.METHODS This prospective study enrolled 60 patients with AGC.All patients received oxaliplatin(130 mg/m^(2),every 3 weeks)and trastuzumab(8 mg/kg loading dose,followed by 6 mg/kg every 3 weeks)for six cycles.Serum carcinoembryonic antigen(CEA),cancer antigen 19-9(CA19-9),and cancer antigen 72-4(CA72-4)were measured before and after treatment.T-lymphocyte subsets,including CD3+,CD4+,CD8+,and CD4+/CD8+ratios,were also evaluated.The clinical response was assessed using the Response Evaluation Criteria in Solid Tumors version 1.1.RESULTS After six cycles of treatment,the CEA,CA19-9,and CA72-4 serum levels significantly decreased compared to baseline levels(P<0.001).The percentages of CD3+and CD4+T lymphocytes increased significantly(P<0.05),whereas the percentage of CD8+T lymphocytes decreased(P<0.05).The CD4+/CD8+ratio also significantly increased after treatment(P<0.05).Patients with a higher decrease in serum tumor markers(≥50%reduction)and a higher increase in CD4+/CD8+ratio(≥1.5-fold)showed better clinical response rates(P<0.05).CONCLUSION Oxaliplatin and trastuzumab combination therapy effectively reduced serum tumor marker levels and modulated T lymphocyte subsets in patients with AGC.Combination therapy not only has a direct antitumor effect,but also enhances the immune response in patients with AGC.Serum tumor markers and T lymphocyte subsets may serve as potential predictive biomarkers for treatment response in patients with AGC receiving combination therapy.

Correlation Study Between T Lymphocyte Subsets and Rheumatoid Arthritis

Objective:To study the effect of Helicobacter pylori infection on rheumatoid arthritis and T-lymphocyte subpopulations in patients with rheumatoid arthritis and to provide a new method for the treatment of rheumatoid arthritis by removing Helicobacter pylori from patients.Methods:60 patients with rheumatoid arthritis admitted to the hospital from May 2022 to May 2023 were selected for the study,and all patients underwent a 13-carbon urea breath test to detect gastric H.pylori and the test results showed that 20 cases were negative and 40 cases were positive.The 40 positive patients were divided into the treatment group(n=20)and non-treatment group(n=20)by random number table method and the treatment group was given anti-Helicobacter pylori treatment,and the non-treatment group was given maintenance rheumatoid basic treatment,comparing the anti-cyclic citrulline peptide(CCP),DS28 score,peripheral blood T-lymphocyte subsets(CD4^(+)T-lymphocytes,CD8^(+)T-lymphocytes,CD4^(+)/CD8^(+)ratio)before and after the treatment of patients by 13-carbon urea respiration test(pylori-negative group,20 patients)and those who were positive for the treatment of H pylori(pylori-positive group,40 patients).Besides,the correlation of peripheral blood T-lymphocyte subsets and disease activity between treatment and non-treatment groups in the pylori-positive group was identified together with the correlation of DS28 scores,TNF-αlevels,sedimentation and immunoglobulin,lymphocyte subsets in the pylori-positive treatment group and positive non-treatment group as well as the level of globulin,lymphocyte subsets,and peripheral blood lymphocytes before and after treatment.Results:Before treatment,CCP,DS28 score,CD8^(+)T lymphocyte level of the pylori-negative group were lower than that of the positive group,and CD4^(+)T lymphocyte and CD4^(+)/CD8^(+)ratio were higher than that of the positive group(P<0.05);after treatment,the indexes of the pylori-positive group improved,and there was no significant difference in the comparison of the indexes with those of the pylori-negative group(P>0.05);the positive treatment group had a DS28(3.19±1.02)points,positive non-treatment group DS28(5.36±1.85)points,non-treatment group DS28 score and CD4^(+)T lymphocytes,CD4^(+)/CD8^(+)negative correlation with CD8^(+)T lymphocytes showed a positive correlation(P<0.05);before the treatment,pylori-positive treatment group and non-treatment group DS28 scores,TNF-αlevels,peripheral blood T lymphocyte subpopulation levels were not significantly different(P>0.05);after treatment,DS28 score,TNF-αlevel,CD8^(+)T of the treatment group were lower than those of the non-treatment group,and CD4^(+)T lymphocytes and CD4^(+)/CD8^(+)ratio were higher than those of the non-treatment group(P<0.05).Conclusion:H.pylori affects the level of T lymphocyte subsets in patients with rheumatoid arthritis,and there is a certain correlation between the two.Removal of H.pylori can improve the level of T lymphocyte subsets,which is important for the treatment of patients with rheumatoid arthritis.

Fas and Bc1-2 EXpression on T Lymphocyte Subsets in the Peripheral Blood of Relapsing Patients with Condyloma Acuminatum

Objective: To study the expression of Fas and Bcl-2proteins on T lymphocyte subsets in the peripheralblood of relapsing patients with condyloma acuminatum(CA) and healthy controls. Methods: Flow cytometry (permeabization andstaining procedure with conjugated antibodies) wasused. Results: We observed that the expression of Fasprotein on CD4^+ T lymphocyte subset of CA patientswas significantly higher than that of healthy controls(P<0.01). Conclusions: Increased expression of Fas proteinon CD4^+ T lymphocyte subset may be a cause of de-creased percentage of CD4^+ T lymphocyte subset. Thisinduces the increased ratio of CD4^+/CD8^+.

Association of T lymphocyte subset counts with the clinical features of colorectal cancer

Background:Colorectal cancer(CRC)is a common gastrointestinal malignancy.The T lymphocyte subsets are important in the develop-ment,invasion and metastasis of tumors,including CRC.Nevertheless,limited research has explored the relationship between T cell subpopu-lations and the clinical characteristics of CRC.This study compared the T lymphocyte subsets in patients with CRC and healthy individuals,and assessed the relationship between these values and clinical characteristics.Methods:Peripheral blood was collected from 100 patients with CRC and 54 healthy individuals.The numbers of CD3^(+)T,CD4^(+)T,and CD8^(+)T lymphocytes,NK cells,and the CD4^(+)T/CD8^(+)T ratio in peripheral blood were measured using flow cytometry,and were compared between CRC patients and healthy individuals.Spearman's correlation analysis was performed to investigate the relationship between the T lymphocyte subsets in patients diagnosed with CRC and the levels of carcinoembryonic antigen(CEA)and thymidine kinase 1(TK1).Receiver operating characteristic(ROC)curves were utilized to evaluate the potential utility of the T lymphocyte counts in predicting lymph node metastasis,vas-cular infiltration,and high Ki-67 expression.Results:The CRC patients had lower counts of CD3^(+)T,CD4^(+)T,and CD8^(+)T lymphocytes compared to the healthy population(P<0.05).However,no significant differences were observed in the CD4^(+)/CD8^(+)ratio or NK cells(P>0.05).Notably,the CD3^(+)T,CD4^(+)T,and CD8^(+)T lym-phocyte counts were higher in patients with stageⅠ-Ⅱdisease,no lymph node metastasis,no vascular invasion,and low Ki-67 expression than in those with stageⅢ,lymph node metastasis,vascular invasion,and high Ki-67 expression(P<0.05).There was a negative association be-tween the CD3^(+)T,CD4^(+)T,and CD8^(+)T lymphocyte counts and CEA and TK1 levels in patients with CRC.The ROC curves demonstrated that CD3^(+)T,CD4^(+)T,and CD8^(+)T lymphocyte counts had significant predictive value for lymph node metastasis,vascular infiltration,and high Ki-67 expression.Conclusions:The peripheral blood CD3^(+)T,CD4^(+)T,and CD8^(+)T lymphocyte counts are related to the clinical traits of patients with CRC and can predict the prognosis of the disease.

PD-1检测联合T淋巴细胞亚群分析对脓毒症患者预后评估的临床研究

目的 检测PD-1表达量联合T淋巴细胞亚群和部分细胞因子分析,评估脓毒症患者的免疫状态及预后。方法 选取符合2016年美国重症医学会/欧洲重症医学会(SCCM/ESICM)脓毒症及脓毒症休克定义Sepsis-3诊断标准,并且符合入组条件的68例患者,根据病情分为脓毒症组和脓毒症休克组,其中脓毒症组30例,脓毒症休克组38例,记录患者一般临床资料,通过ELISA法检测PD-1,抽取外周血送检,检查项目包括血常规、淋巴细胞亚群测定(T辅助淋巴细胞CD4^(+)与T抑制淋巴细胞CD8^(+))、降钙素原、白介素-6、超敏C反应蛋白。结果 2组患者一般资料比较差异无统计学意义(P>0.05),但2组患者急性生理与慢性健康评分和序贯器官衰竭的评分比较差异有统计学意义(P<0.05);脓毒症休克组的PD-1较脓毒症组表达水平高,差异有统计学意义(P<0.05),但淋巴细胞计数、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)较脓毒症组低(P<0.05);2组患者的感染指标降钙素原及炎症指标白介素-6和超敏C反应蛋白比较差异有统计学意义(P<0.05),脓毒症休克组较脓毒症组检测值更高(P<0.05);总T淋巴细胞相比,2组患者差异无统计学意义(P>0.05);脓毒症休克组患者的住ICU时间、14天病死率、28天病死率均较脓毒症组明显升高(P<0.05);PD-1表达水平、CD4^(+)T细胞是影响脓毒症患者死亡的独立危险因素。结论 脓毒症和脓毒症休克患者早期即出现免疫抑制,脓毒症休克组患者免疫抑制更严重,预后更差。

T淋巴细胞亚群、IL-6在胃癌患者中的表达及其与预后的相关性

目的分析外周血T淋巴细胞亚群及白细胞介素-6(interleukin-6,IL-6)在胃癌患者中的表达,探究其与预后的相关性。方法选取2021年6月至2023年6月连云港市第二人民医院收治的106例胃癌患者为试验组,入院次日检测其外周血T淋巴细胞亚群(CD3^(+)、CD4^(+)、CD8^(+))及IL-6水平。选取同时段于连云港市第二人民医院进行体检的健康者80例为对照组,体检当日检测其外周血T淋巴细胞亚群及IL-6水平。比较两组T淋巴细胞亚群及IL-6水平。胃癌患者院外随访6个月,根据患者死亡、存活情况将其分为预后不良组(17例)、预后良好组(89例)。预后不良组男10例(58.82%),女7例(41.18%),年龄(60.47±5.89)岁;文化程度:中学及以上9例(52.94%),中学以下8例(47.06%)。预后良好组男55例(61.80%),女34例(38.20%),年龄(60.08±5.71)岁;文化程度:中学及以上32例(35.96%),中学以下57例(64.04%)。logistic回归分析影响胃癌患者预后的因素。采用受试者操作特征曲线(ROC)评估外周血T淋巴细胞亚群及IL-6预测胃癌患者预后的价值。采用t检验和χ^(2)检验。结果试验组CD3^(+)、CD4^(+)水平低于对照组[(55.27±8.72)%比(68.97±6.45)%、(26.42±10.21)%比(38.12±5.07)%],CD8^(+)、IL-6水平高于对照组[(33.36±6.02)%比(24.66±3.75)%、(6.97±3.29)ng/L比(3.62±1.01)ng/L],差异均有统计学意义(t=-11.821、-9.413、11.360、8.803,均P<0.05)。预后不良组CD3^(+)、CD4^(+)水平低于预后良好组[(45.12±10.06)%比(57.21±6.97)%、(20.01±10.12)%比(27.64±9.81)%],CD8^(+)、IL-6水平、肿瘤分期Ⅳ期患者占比高于预后良好组[(40.12±6.01)%比(32.07±5.12)%、(9.75±3.16)ng/L比(6.44±3.05)ng/L、70.59%(12/17)比32.58%(29/89)],差异有统计学意义(t=-6.068、-2.924、5.774、4.077,χ^(2)=8.692,均P<0.05)。logistic回归分析显示,肿瘤分期、CD3^(+)、CD8^(+)、IL-6水平是影响胃癌患者预后的因素(均P<0.05)。CD3^(+)、CD8^(+)、IL-6预测患者预后不良的ROC下面积分别为0.847、0.853、0.768。结论胃癌患者CD3^(+)、CD4^(+)低表达,CD8^(+)及IL-6高表达。CD3^(+)、CD8^(+)、IL-6水平是影响胃癌患者预后的因素。

超声心动图参数及外周血T淋巴细胞亚群、NF-κB、CD64水平预测新生儿败血症预后的价值

【目的】探讨超声心动图参数及外周血T淋巴细胞亚群、核因子-κB(NF-κB)、簇分化抗原64(CD64)水平预测新生儿败血症预后的价值。【方法】选取2020年1月至2023年2月本院收治的95例新生儿败血症,根据预后情况将其分为存活组(n=80)和死亡组(n=15)。比较两组患儿超声心动图参数[左室短轴缩短率(FS)、升主动脉内径(AAO)、左室射血分数(LVEF)]、心肌损伤标志物[肌酸激酶(CK)、肌酸激酶同工酶(CK-MB)]、T淋巴细胞亚群(CD3^(+)、CD4^(+)、CD8^(+))、NF-κB、CD64水平;采用Logistic多因素回归分析新生儿败血症预后不良的相关影响因素;采用受试者工作特征(ROC)曲线分析心电图指标及实验室指标预测新生儿败血症预后的临床价值。【结果】两组患儿肌酸激酶CK、CK-MB水平比较,差异无统计学意义(P>0.05);存活组FS、AAO及LVEF高于死亡组患儿,差异有统计学意义(P<0.05)。两组患儿CD8^(+)水平比较,差异无统计学意义(P>0.05);存活组患儿CD3^(+)、CD4^(+)水平高于死亡组,NF-κB、CD64水平低于死亡组,差异有统计学意义(P<0.05)。两组患儿中性粒细胞与淋巴细胞比值(NLR)、C反应蛋白(CRP)水平比较,差异无统计学意义(P>0.05);存活组患儿白细胞计数(WBC)低于死亡组,差异有统计学意义(P<0.05)。Logistic多因素回归分析显示:FS、LVEF、CD64是影响新生儿败血症预后的相关因素(P<0.05)。FS、LVEF、CD64联合预测新生儿败血症预后的ROC曲线下面积为0.948,明显高于各指标单独预测的0.827、0.895和0.877(P<0.05)。【结论】FS、LVEF联合CD64检测对新生儿败血症预后有良好的预测价值,临床可通过密切监测上述指标及时判断新生儿败血症预后,采取相关干预措施。

Distribution of natural killer cells and T-lymphocyte subsets in peripheral blood,gallbladder cancer and surrounding tissue

BACKGROUND: The patient with malignant tumor always show immunologic function drawback and ingravescent with tumor development, especially in the aspect of cell-mediated immunity. This study was undertaken to define the relationship between the immune function of local cells and cancer development by investigating the distribution of natural killer (NK) cells and T-lymphocyte subsets in peripheral blood, the cancer tissue and the tissue surrounding gallbladder carcinoma. METHODS: The numbers of CD4(+) and CD8(+) T-lymphocytes and NK cells were measured by flow cytometry in samples taken from gallbladder cancer tissue, the surrounding tissues and peripheral blood of 38 patients, and compared with the numbers in the peripheral blood and gallbladder tissue of 30 patients with cholecystitis as controls. RESULTS: The numbers of CD4(+) and CD8(+) T-cells and NK cells in gallbladder cancer tissues were significantly higher than those in the surrounding tissue and gallbladder with gallstone. However, the ratio of CD4(+)/CD8(+) was lower in the cancer tissue than that in the surrounding tissue and tissue from gallbladders with gallstones. The distribution of CD4(+) and CD8(+) T-cells and NK cells in mucous membrane of cholecystitis gallbladder and that in the tissue surrounding gallbladder cancer were significantly different. CONCLUSIONS: Disproportionate and imbalanced distribution of NK cells and subsets of T-lymphocytes occurs in the mucous membrane proper of gallbladder cancer and surrounding tissue. Although gallbladder cancer tissue has higher expressions of CD4(+), CD8(+) and NK cells, the immune function is low or in an inhibited state. In gallbladder cancer immunization therapy, local cellular immunological function should be enhanced and the protective barrier improved.

Effects of Intraoperative Administration of Dexmedetomidine on the Percentage of T-Lymphocyte Subsets and Natural Killer Cells in Patients with Colorectal Cancer

Study Objective: To observe the effect of dexmedetomidine (DEX) on T-lymphocyte subsets and natural killer (NK) cells in the peripheral blood of perioperative patients with colorectal cancer. Design: A random double-blind control clinical study. Setting: A university hospital. Patients: Forty patients with colorectal cancer, ASA I-П. Interventions: All patients were randomly divided into a DEX group (n = 20) and a control group (n = 20). Before induction of anesthesia, epidural catheters were placed in the L1-L2 or T12-L1 intervertebral spaces. The DEX group received 1 μg/kg of DEX (200 μg/50 ml) intravenously for 15 min prior to the surgery, which was then infused at a rate of 0.5 μg/kg/h until 30 min before the end of the surgery. The control group received an intravenous infusion of saline (50 ml) instead of DEX during the same periods as the DEX group. All patients received routine anesthesia and postoperative analgesia. Measurements: Blood samples from all patients were collected at the following time points: before anesthesia (T0), 24 h after surgery (T1), 48 h after surgery (T2) and 72 h after surgery (T3). Changes in T-lymphocyte subsets (CD3+, CD4+, CD8+, CD4+/CD8+) and NK cells were determined by flow cytometry. Main Results: Compared with the control group, the percentages of CD3+ and CD4+ cells and the CD4+/CD8+ ratio in the DEX group increased significantly from T1 to T3

Effects of TSH inhibition after total thyroidectomy on Tg, VEGF, TSGF, CD44V6, sIL-2R and T lymphocyte subsets in patients with differentiated thyroid carcinoma

Objective:To study the effects of TSH inhibition after total thyroidectomy on Tg, VEGF, TSGF, CD44V6, sIL-2R and T lymphocyte subsets in patients with differentiated thyroid carcinoma (DTC).Methods: A total of 100 patients with DTC in our hospital from January 2014 to January 2017 were enrolled in this study. The subjects were divided into the control group (n=50) and the treatment group (n=50) randomly. The control group was treated with thyroid hormone replacement therapy, the treatment group was treated with levothyroxine sodium oral therapy, the two groups were treated for 1 week. The serum Tg, VEGF, TSGF, CD44V6, sIL-2R and peripheral blood CD3+, CD4+, CD8+ of the two groups before and after treatment were compared.Results:There were no significant differences of the serum Tg, VEGF, TSGF, CD44V6, sIL-2R of the two groups before treatment. The serum Tg, VEGF, TSGF, CD44V6, sIL-2R of the two groups after treatment were significantly lower than before treatment, and that of the treatment group after treatment were significantly lower than the control group. There were no significantly differences of the peripheral blood CD3+, CD4+, CD8+ of the two groups before treatment. The peripheral blood CD3+, CD4+ of the two groups after treatment were significantly higher than before treatment, the peripheral blood CD8+ of the two groups after treatment were significantly lower than before treatment, and that of the treatment group after treatment were significantly better than the control group.Conclusion:TSH inhibition after total thyroidectomy for patients with DTC can reduce the serum Tg, VEGF, TSGF, CD44V6, sIL-2R levels, improve the cellular immunity function, and it was worthy clinical application.

THE CHANGES OF PERIPHERAL BLOOD T LYMPHOCYTE SUBSETS IN PATIENTS WITH PRIMARY HEPATIC CARCINOMA BOTH PRE-TACE AND POST-TACE

Objective To observe the variations of the cellular immunological function in patients with primary hepatic carcinoma both pre-TACE(transcatheter arterial chemoembolization,TACE).Methods T lymphocyte subset CD4,CD8 and CD4/CD7 ratio in 45 patients with primary hepatic carcinoma both pre-TACE and post-TACE were measured by flow Cytometer,and compared with the result of T lymphocyte subset in 19 healthy people as normal control samples.Results The CD4 and CD4/CD8 ratio in patients with primary hepatic carcinoma were significantly lower than those in normal control(P<0.05),while CD8 higher(P<0.05);The CD4 and CD4/CD8 ratio in patients with primary hepatic carcinoma were much more lower after TACE than those before TACE(P<0.05),while CD8 was higher but had no significant difference(P>0.05).Conclusion The cellular immunological function in patients with primary hepatic carcinoma decreased and is much more lower after TACE.

SAA、IL-6、CRP及T淋巴细胞亚群联合检测在类风湿性关节炎患者中的应用价值

目的探讨血清淀粉样蛋白A(SAA)、白细胞介素-6(IL-6)、C反应蛋白(CRP)及T淋巴细胞亚群联合检测在类风湿性关节炎患者中的应用价值并进行相关危险因素分析。方法选取2020年10月至2023年5月在玉林市第一人民医院确诊为类风湿性关节炎的患者66例为类风湿关节炎组,同期选择体检健康者33名为对照组,比较两组SAA、IL-6、CRP及T淋巴细胞亚群水平的差异。结果类风湿性关节炎组SAA、IL-6、CRP、CD3^(+)T%及CD4^(+)T%水平高于对照组,CD8^(+)T%水平低于对照组,差异有统计学意义(P<0.05)。Spearman相关分析结果显示,IL-6与SAA、CRP、CD3^(+)T%及CD4^(+)T%呈正相关(P<0.05);CD4^(+)T%与SAA、IL-6、CRP、CD3^(+)T%呈正相关(P<0.05);IL-6、CD4^(+)T%分别与CD8^(+)T%呈负相关(P<0.05)。二元logistic回归分析显示,SAA、IL-6、CRP、CD3^(+)T%及CD4^(+)T%是类风湿性关节炎患者的危险因素,而CD8^(+)T%是该类患者保护因素(P<0.05)。结论类风湿性关节炎患者SAA、IL-6、CRP是类风湿性关节炎患者的危险因素,T淋巴细胞亚群免疫异常与该疾病发生发展密切相关,多项目联合检测对类风湿性关节炎临床诊疗及评估病情有重要价值。

信迪利单抗联合化疗对晚期胃癌患者近期疗效及血清CEA sTim-3 sLAG-3和T淋巴细胞亚群的影响

目的:探究信迪利单抗联合化疗对晚期胃癌患者近期疗效及血清癌胚抗原(CEA)、免疫功能和T淋巴细胞亚群的影响。方法:研究样本选取我院2020年5月至2022年5月就诊84例晚期胃癌患者,分组方式为分段随机化法(观察组和对照组),每组各42例。对照组采用常规化疗进行处理,观察组加用信迪利单抗,两组均持续治疗3个疗程(3个月)。记录两组患者化疗1个月后临床效果、治疗期间毒副反应发生情况,比较两组治疗前、治疗3疗程后血清肿瘤标志物[糖链抗原(CA)、癌胚抗原(CEA)、MG抗原(MG-Ag)]、免疫功能(sTim-3、sLAG-3)、T淋巴细胞水平(CD3+、CD4+、CD8+)的变化。治疗后随访1年,记录两组生存率。结果:化疗1个月后,观察组临床有效率高于对照组,毒副作用发生情况无明显差异(P>0.05)。治疗3疗程后两组CA、CEA、MG-Ag、sTim-3、sLAG-3水平显著降低,且观察组低于对照组(P均<0.05),两组CD3+、CD4+均降低,且观察组高于对照组,CD8+均升高,且观察组低于对照组(P均<0.05)。观察组1年生存率显著高于对照组(P<0.05)。结论:信迪利单抗联合化疗对晚期胃癌患者近期疗效显著且安全性较高,可有效改善患者免疫功能,减轻肿瘤负荷。

循环CD4^(+)CD45RA^(+)CD62L^(+)T细胞与接受EGFR-TKI治疗的转移性非小细胞肺癌预后相关

目的探索外周血循环淋巴细胞的基线水平及动态变化与接受表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)治疗的EGFR突变阳性的转移性非小细胞肺癌患者预后之间的相关性。方法设计一个回顾性队列,包括在北京协和医院接受EGFR-TKI治疗的40例非小细胞肺癌患者。在EGFR-TKI治疗期间,使用流式细胞仪测量术收集外周血循环淋巴细胞亚群进行动态监测,并通过电话随访每位患者的生存情况,分别比较基线以及治疗1月后外周血循环淋巴细胞亚群与无进展生存期(PFS)和总生存期(OS)的关系。结果在接受EGFR-TKI治疗的患者中,更高的基线循环CD4^(+)CD45RA^(+)CD62L^(+)T细胞计数与更高的肿瘤治疗应答相关(P<0.001)。整个人群的PFS为27.1个月,而OS未达到。然而,基线CD4^(+)CD45RA^(+)CD62L^(+)T细胞计数与中位PFS无相关性。此外,在EGFR-TKI治疗期间,CD4^(+)CD45RA^(+)CD62L^(+)T细胞计数稳定或升高的患者的PFS明显长于CD4^(+)CD45RA^(+)CD62L^(+)T细胞计数降低的患者(29.1个月对比9.4个月;P<0.001)。结论更高的基线循环CD4^(+)CD45RA^(+)CD62L^(+)T细胞计数与更好的EGFR-TKI治疗应答相关,CD4^(+)CD45RA^(+)CD62L^(+)T细胞计数的动态变化与PFS延长有关。

血清淀粉样蛋白A、白细胞介素-6及T淋巴细胞亚群相关指标在系统性红斑狼疮活动期的表达水平分析

目的:分析血清淀粉样蛋白A(SAA)、白细胞介素-6(IL-6)及T淋巴细胞亚群相关指标在系统性红斑狼疮(SLE)活动期的表达水平。方法:选取2020年10月—2023年5月玉林市第一人民医院收治的SLE患者200例作为研究对象,根据SLE活动指数积分表评分分为SLE稳定期组与SLE活动期组,各100例,另选取同期于玉林市第一人民医院进行健康体检的健康人100例作为对照组。检测不同人群SAA、IL-6及T淋巴细胞亚群相关指标水平。结果:SLE稳定期组及SLE活动期组CD3%、CD8%、SAA、IL-6水平均高于对照组,SLE稳定期组SAA、IL-6水平低于SLE活动期组,SLE稳定期组CD4%高于对照组与SLE活动期组,差异有统计学意义(P<0.05)。SLE稳定期组及SLE活动期组CD3^(+)、CD4^(+)、CD8^(+)均小于对照组,且SLE活动期组CD3^(+)、CD4^(+)、CD8^(+)均小于SLE稳定期组,差异有统计学意义(P<0.05)。结论:SAA、IL-6及T淋巴细胞亚群相关指标在SLE患者中均有异常改变,SLE患者活动期T淋巴细胞亚群绝对计数低于稳定期患者,对于SLE的临床诊治具有一定参考价值。

慢性乙型肝炎病毒感染患者CD8^(+)T细胞中LAG-3的表达特征及临床意义

【目的】探讨慢性乙型肝炎病毒(HBV)感染患者CD8^(+)T细胞中淋巴细胞活化基因-3(LAG-3)的表达特征及临床意义。【方法】选取2019年4月至2020年4月本院收治的60例慢性HBV患者(HBV组),另外选取同期于本院体检的60例健康志愿者作为对照组。比较两组CD8^(+)T细胞中LAG-3表达水平、表达强度、分布频数,并测定细胞内白介素-10(IL-10)、人类白细胞抗原-DR(HLA-DR)、干扰素-γ(IFN-γ)、转录因子T-bet(T-bet)表达水平,分析LAG-3调控CD8^(+)T细胞的机制。【结果】HBV组LAG-3的表达水平、表达强度高于对照组(P<0.05)。HBV组LAG-3阳性亚群的IL-10表达水平高于阴性亚群,且HBV组LAG-3阴性亚群、阳性亚群的IL-10表达水平均高于对照组(P<0.05)。HBV组LAG-3阳性亚群的HLA-DR表达水平低于阴性亚群,且HBV组LAG-3阴性亚群、阳性亚群的HLA-DR表达水平均低于对照组(P<0.05)。HBV组LAG-3阳性亚群的IFN-γ表达水平低于阴性亚群,且HBV组LAG-3阴性亚群、阳性亚群IFN-γ表达水平低于对照组(P<0.05)。HBV组LAG-3阳性亚群的T-bet表达水平低于阴性亚群,且HBV组阴性亚群、阳性亚群IFN-γ表达水平低于对照组(P<0.05)。【结论】慢性HBV感染者在炎症作用下导致CD8^(+)T细胞内LAG-3表达水平增高,而LAG-3能通过影响IL-10、HLA-DR、IFN-γ、T-bet的表达,下调CD8^(+)T对IFN-γ的分泌量,致T细胞消耗量增加。

Effect of rabdosia rubescens combined with new assistant chemotherapy on serum CA199, CEA, CA15-3 and T lymphocyte subsets in patients with breast cancer

Objective:To study the effects of Rabdosia rubescens combined with neoadjuvant chemotherapy on serum CA199, CEA, CA15-3 levels and T lymphocyte subsets in patients with breast cancer.Methods: A total of 70 patients with breast cancer in our hospital were enrolled as the subjects of this study. The subjects were divided into control group (n=35) and treatment group (n=35) randomly. Patients in the control group were treated with new assistant chemotherapy, while those who were in the treatment group were treated with rabdosia rubescens combined with new assistant chemotherapy. The two groups of patients were treated for 3 periods. The serum CA199, CEA, CA15-3 levels and peripheral blood CD4+, CD8+, CD4+/CD8+ cells of the two groups before and after treatment were compared.Results:There were no significantly differences among the serum CA199, CEA, CA15-3 levels and peripheral blood CD4+, CD8+, CD4+/CD8+ cells of the two groups before treatment. The serum CA199, CEA and CA15-3 levels of the two groups after treatment were significantly lower than those before treatment, besides, the serum CA199, CEA and CA15-3 levels of the treatment group were significantly lower than those of the control group. The peripheral blood CD4+, CD4+/CD8+ cells of the control group after treatment were significantly lower than before treatment, and the peripheral blood CD4+, CD4+/CD8+ cells of the treatment group after treatment were significantly higher than those of the control group.Conclusion:Rabdosia rubescens combined with new assistant chemotherapycan can significantly reduce the serum CA199, CEA and CA15-3 levels, and improve peripheral blood CD4+, CD8+, CD4+/CD8+ levels of patients with breast cancer. It is worthy of clinical application.

Effects of combined treatment of bronchial arterial chemoembolization and radioactive particle implantation on tumor markers and T lymphocyte subsets in locally advanced non-small cell lung cancer

Objective: To investigate the effects of bronchial arterial chemoembolization combined with radioactive particle implantation on the level of serum tumor markers and T lymphocyte subsets in patients with locally advanced non-small cell lung cancer. Methods: A total of 91 cases of locally advanced non-small cell lung cancer patients according to the random data table were divided into the control group (n=45) and observation group (n=46) according to the random data table. Patients in the control group was treated with bronchial arterial chemoembolization, on the basis of the control group, patients in the observation group were treated with radioactive particle implantation, the serum tumor markers and T lymphocyte subsets of the two groups were compared before and after treatment. Results: The levels of CEA, NSE, CA125, CD4+, CD8+, CD4+/CD8+ and NK in the two groups before the treatment were not statistically significant. Compared with the group before treatment, levels of CEA, NSE, CA125and CD8+ of the two groups after treatment were significantly decreased, and after treatment the level of CEA, NSE, CA125and CD8+ in the observation group was significantly lower than those of the control group;The levels of CD4+, CD4+/CD8+ and NK in the two groups after treatment were significantly higher than those in the group before treatment, and the observation group levels were significantly higher than those of the control group. Conclusion: Bronchial artery embolization combined with radioactive particle implantation for locally advanced non-small cell lung cancer, can effectively reduce the serum tumor markers level, improve the level of T cell subsets of patients, has important clinical value.

外周血T淋巴细胞亚群、NK细胞、B细胞及IL-6在不同分期慢性肾脏病患者中的表达及临床意义

目的:探讨外周血T淋巴细胞亚群、自然杀伤细胞(NK细胞)、B细胞及白细胞介素-6(IL-6)在不同分期慢性肾脏病(chronic kidney disease,CKD)患者中的表达及临床意义。方法:选取盐城市中医院肾内科2022年10月—2023年6月收治的80例CKD 3~5期患者设为CKD组,另外选择同期21例健康体检者设为对照组,其中CKD组患者根据肾小球滤过率水平分为CKD 3期组、CKD 4期组、CKD 5期组。用流式细胞术检测外周血T淋巴细胞亚群(CD4^(+)T细胞、CD8^(+)T细胞)、NK细胞、B细胞,用酶联免疫吸附试验检测IL-6水平。比较以上指标在不同分期CKD患者中的表达,并采用Spearman相关性分析以上指标与CKD严重程度的相关性。结果:CKD 3期组、CKD 4期组、CKD 5期组CD4^(+)T细胞、CD8^(+)T细胞、NK细胞、B细胞均明显低于对照组,且CD4^(+)T细胞、CD8^(+)T细胞、NK细胞、B细胞随CKD严重程度加重逐渐降低,差异均有统计学意义(P<0.05);CKD 3期组、CKD 4期组、CKD 5期组IL-6水平明显高于对照组,且IL-6水平随CKD严重程度加重逐渐升高,差异均有统计学意义(P<0.05);IL-6水平与CKD分期呈负相关,CD4^(+)T细胞、CD8^(+)T细胞、NK细胞、B细胞与CKD分期呈正相关(P<0.05)。结论:随着CKD进展,患者的免疫功能受到显著影响,外周血T淋巴细胞亚群、NK细胞、B细胞及IL-6在评估CKD患者疾病进展中有重要临床意义。

PD-1抑制剂联合SOX方案治疗晚期胃癌患者的疗效及对外周血T淋巴细胞亚群水平的影响

目的 分析程序性死亡受体-1(PD-1)抑制剂联合SOX方案(替吉奥联合奥沙利铂)治疗晚期胃癌患者的疗效及对外周血T淋巴细胞亚群水平的影响。方法 回顾性分析90例晚期胃癌患者资料,按不同治疗方案分为对照组(接受SOX方案治疗)、研究组(接受PD-1抑制剂联合SOX方案治疗),各45例。比较2组患者临床疗效、生命质量测定量表体系之胃癌量表(QLICP-ST)、卡式评分(KPS)及不良反应;比较2组患者血清肿瘤标志物糖类抗原724(CA724)、胃蛋白酶原Ⅰ(PG-Ⅰ)、癌胚抗原(CEA)水平、外周血T淋巴细胞亚群(CD3+、CD4+、CD4+/CD8+)。结果 研究组疾病控制率(75.56%)高于对照组(55.56%)(P<0.05);治疗后研究组QLICP-ST评分、KPS评分高于对照组(P<0.05);2组患者恶心呕吐、肝损伤、便秘腹泻、骨髓抑制、皮疹瘙痒、神经毒性、心脏毒性等不良反应发生率比较,差异无统计学意义(P>0.05)。治疗后研究组PG-I高于对照组,CA724、CEA低于对照组(P<0.05);治疗后研究组CD3+、CD4+、CD4+/CD8+高于对照组(P<0.05)。结论 PD-1抑制剂联合SOX方案治疗晚期胃癌可有效控制疾病进展,减轻免疫抑制,改善患者体能状态,提高患者生存质量,安全性高。